The crosstalk between oxidative stress, altered metabolic activity, immune activation and inflammation provides more possible targets to treat CHM; for example, targeting neuroinflammation by inhibiting IL-1β or MYD88 pathways has shown some retinal improvement in a rd10 mouse model [76]. This evidence concerns the gene MYD88 and choroideremia.